Pisa

• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Pending
  2025-523495-23-00 5 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect … Pending
  2025-523521-18-00 5 Metastatic Colorectal Cancer
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double- … Pending
  2025-523868-20-00 4 Bile acid diarrhoea
• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi … Pending
  2025-524367-20-00 4 Adult patients with primary mitochondrial disease
• Study to Assess K1-70 in Participants with Active Thyroid Eye Disease Recruiting
  2024-519292-26-00 4 2026-05-28 Graves’ disease and active thyroid eye disease
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting
  2025-520660-18-00 6 2026-05-08 Heart Failure
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol … Recruiting
  2025-521845-26-00 5 2026-03-02 BP-I mania or mania with mixed features
• A Phase III, randomized, controlled study of furazidin for bacterial vaginosis. Recruiting
  2024-515332-80-00 5 2026-02-23 Bacterial vaginosis
• A phase 3 efficacy and safety study of fosmanogepix for the treatment of adult patients with invasive mold infections Recruiting
  2024-516216-16-00 5 2026-02-13 Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lo
• A study to learn more about the change in the blood levels of transthyretin when participants with transthyretin amyloidosis with cardiomyop … Recruiting
  2025-521831-35-00 6 2026-02-12 Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
• Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano … Recruiting
  2022-503140-41-00 5 2025-12-19 Melanoma
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer Recruiting
  2025-521277-14-00 4 2025-12-09 Non-muscle invasive bladder cancer (NMIBC)

Showing 49–72 of 550 trials